Yoichi Nakanishi
Research Institute for Diseases of the Chest
Faculty of Medicine
Kyushu University
Fukuoka
Japan
Name/email consistency: high
- Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors. Nakanishi, Y., Takayama, K., Wataya, H., Izumi, M., Minami, T., Takano, K., Inoue, K., Osaki, S., Kimotsuki, K., Harada, T., Hara, N. Chemotherapy (2002)
- Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. Nakanishi, Y., Pei, X.H., Takayama, K., Bai, F., Izumi, M., Kimotsuki, K., Inoue, K., Minami, T., Wataya, H., Hara, N. Am. J. Respir. Cell Mol. Biol. (2000)
- Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer. Nakanishi, Y., Kawasaki, M., Bai, F., Takayama, K., Pei, X.H., Takano, K., Inoue, K., Osaki, S., Hara, N., Kiyohara, C. Oncology (1999)
- Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. Fukuoka Lung Cancer Study Group. Nakanishi, Y., Kawarada, Y., Hirose, N., Ninomiya, K., Miyazaki, M., Miyazaki, N., Kurita, Y., Kanegae, H., Ohgushi, O., Ogata, K., Yamazaki, H., Inutsuka, S., Hara, N. Cancer Chemother. Pharmacol. (1998)